Drugs / G001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05007808 | Jan 2021 → Jan 2023 | osteoarthritis, knee | BUZZZ Pharmaceuticals Limited | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2022-05-18 | ModernaTX, Inc. | Results IAVI and Moderna Launch First-in-Africa Clinical Trial of mRNA HIV Vaccine Development Program q4web.com ↗
Recent findings from the Phase I clinical trial IAVI G001 showed that vaccination with the HIV immunogen eOD-GT8 60mer as a recombinant protein safely induced the targeted immune responses in 97% of recipients (healthy U.S. adults). |
| 2021-04-14 | ModernaTX, Inc. | Results Moderna Announces Clinical Progress from its Industry-Leading mRNA Vaccine Franchise and Continues Investments to Accelerate Pipeline Development q4web.com ↗
This Phase 1 study confirms that vaccines can induce broadly neutralizing antibodies, a necessary strategy to develop an HIV vaccine. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-05-18 | ModernaTX, Inc. | IAVI and Moderna Launch First-in-Africa Clinical Trial of mRNA HIV Vaccine Development Program q4web.com ↗ |
| 2021-04-14 | ModernaTX, Inc. | Moderna Announces Clinical Progress from its Industry-Leading mRNA Vaccine Franchise and Continues Investments to Accelerate Pipeline Development q4web.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | G001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05007808 ↗ |
| Route | Topical | “Non-steroidal anti-inflammatory drug for topical administration” NCT05007808 ↗ |